Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
IPO Year: 2019
Exchange: NASDAQ
Website: precisionbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $34.00 | Market Perform → Outperform | BMO Capital Markets |
| 4/30/2024 | $19.00 | Buy | Guggenheim |
| 6/17/2022 | $7.00 | Outperform | BMO Capital Markets |
| 6/9/2022 | Outperform → Mkt Perform | William Blair | |
| 9/10/2021 | $23.00 → $26.00 | Buy | Stifel |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
DEFA14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
DEF 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
PRE 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
10-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00
Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00
BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00
William Blair downgraded Precision BioSciences from Outperform to Mkt Perform
Stifel reiterated coverage of Precision BioSciences with a rating of Buy and set a new price target of $26.00 from $23.00 previously
Jonestrading initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $27.00
JonesTrading initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $27.00
Jonestrading initiated coverage of Precision BioSciences with a rating of Buy
JPMorgan Chase & Co. reiterated coverage of Precision BioSciences with a rating of and set a new price target of $14.00 from $10.00 previously
Fastest customizable press release news feed in the world
First infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following administration of ECUR-506 Statistically significant reductions in the annualized rate of HAEs and hyperammonemic crises (HACs) observed in the completed low-dose cohort (n=3), with 57% (p =0.018) and 65% (p =0.011) reductions, respectively, in pre-dose to post-dose rates of events per person-year Data presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo t
– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young as 2 years of age – – Greater efficacy with earlier intervention further differentiates PBGENE-DMD from microdystrophin approaches – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new preclinical data from its PBGENE-DMD pr
Preliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data cutoff date. HACs are defined as plasma ammonia levels above 100µmol/L with neurologic status change. Data from these cohorts also demonstrate approximately 52% reduction in the annualized rate of HACs following ECUR-506 administration. HACs are the most clinically significant neurometabolic manifestation of ornithine transcarbamylase (OTC) deficiency. Reducing or preventing these crises is a key treatment goal, clinically meaningful measure of patient benefit, and an im
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more de
- Arkansas Children's Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing treatment for Duchenne muscular dystrophy (DMD), is being evaluated in the Phase 1/2 FUNCTION-DMD study. PBGENE-DMD is Precision's wholly owned in vivo gene editing pr
iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that clinical data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, and the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, taking place May 17-20, 2026 in Puerto Rico. The oral presentation at ASGCT will include preliminary data from study participants in the first three dose cohorts (n=7
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. The accepted abstract highlights new data demonstrating compelling efficacy observed in early-juvenile mice supporting the potential benefit of earlier intervention with PBGENE-DMD in younger patient populations. These data build on previously shared u
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of an inducement award of 7,094 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan") in connection with their commencement of employment. The award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am ET Webcast Link: Precision BioSciences Virtual Presentation Link If you are interested in meeting with the Precision team during the conference, please reach out to your Needham representative. A replay of the presentation wil
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical development timelines ECUR-506 selected as one of up to nine programs annually Participation enables additional FDA engagement on CMC strategy ahead of a potential BLA submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company's investigational in vivo targeted gene insertion therapy
Live Leadership Updates
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE
New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences. Ms. Blanche is a human resources (HR) executive with over 25 years of strategic business partnership and enterprise leadership experience in the pharmaceutical and financial services industries. She most recently joins Precision BioSciences from Bristol-Myers Squibb (BMS) where she was Seni
New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc., and Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2021110800541
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the Company's President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021. Mr. Amoroso will succeed Matt Kane, Co-Founder, President and Chief Executive Officer, who is expected to serve as an advisor to the Company to help ensure a smooth transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005216/en/M
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company's Interim Chief Financial Officer since December 2020. He will continue to serve as the company's principal financial officer, reporting directly to Matt Kane, Chief Executive Officer and oversee the company's finance, corporate communications, and investor relations functions. Shane Barton, the Company's Vice President
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company's Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies, including myelodysplastic syndromes, acute leukemia, multiple myeloma, and lymp
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Stanley R. Frankel, M.D. has been appointed as a Director on the Company's Board of Directors and a member of the Board's Science and Technology (S&T) Committee. Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblast
DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a Chief Executive Officer transition plan and the initiation of a public search for a new CEO. Matt Kane, Co-Founder and Chief Executive Officer, is expected to continue in his current leadership capacity and as a board member until his successor has been identified. Mr. Kane will also serve as an advisor for a period of time after the next CEO is hired ensuring a smooth transition. During the transition period, Mr. Kane will continue t
This live feed shows all institutional transactions in real time.
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G - PRECISION BIOSCIENCES INC (0001357874) (Subject)
Live finance-specific insights
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more de
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may en
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics ma
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 - - Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time - - Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 - - Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing i
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may ena
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enab
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more inten
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabili